Kelly S. Chien, M.D.
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2013 | Baylor College of Medicine, Houston, Texas, US, MD |
| 2008 | Massachusetts Institute of Technology, Cambridge, Massachusetts, US, SB in Chemical Engineering |
| 2008 | Massachusetts Institute of Technology, Cambridge, Massachusetts, US, SB in Biology |
Postgraduate Training
| 2019-2020 | Hematology Chief Fellow, Hematology/Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2019 | Clinical Fellowship, Hematology/Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2016 | Clinical Residency, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas |
| 2013-2014 | Clinical Internship, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas |
Licenses & Certifications
| 2020 | Hematology |
| 2020 | Medical Oncology |
| 2016 | American Board of Internal Medicine Certification |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Medicine, New York University Langone Medical Center, New York, NY, 2016 - 2017
Institutional Committee Activities
Vice Chair, Institutional Review Board, 2024 - Present
Member, Joint Steering Committee for the Rigel/MDACC Alliance, 2023 - Present
Member, Institutional Review Board, 2023 - Present
Member, Utilization Review Committee, 2022 - Present
Member, Academic Review Committee, 2022 - Present
Leukemia MD Champion, PROSPECT Trial, 2021 - Present
Committee Member, Clinic to ACCC Handoff Team, 2021 - Present
Honors & Awards
| 2022 | Travel Grant, European Hematology Association |
| 2022 | Waun Ki Hong Award for Excellence in Team Science, University of Texas MD Anderson Cancer Center |
| 2020 | Kimberly Patterson Fellowship in Leukemia Research, University of Texas MD Anderson Cancer Center |
| 2020 | Waun Ki Hong Award for Achievement in Clinical Investigation, University of Texas MD Anderson Cancer Center |
| 2019 | Conquer Cancer Foundation Young Investigator Award, American Society of Clinical Oncology |
| 2019 | Merit Award, American Society of Clinical Oncology Annual Meeting |
| 2019 | Oncology Fellows Program Participant, National Comprehensive Cancer Network Annual Meeting |
| 2018 | Abstract Achievement Award, American Society of Hematology Annual Meeting |
| 2016 | Internal Medicine Resident Teaching Award Honorable Mention, University of Texas Southwestern Medical Center |
| 2014 | Internal Medicine Intern Teaching Award Honorable Mention, University of Texas Southwestern Medical Center |
| 2008 | Top 5, MIT 6.270 Autonomous Robot Competition |
| 2004 | National Merit Scholar, National Merit Scholarship Program |
| 2004 | Semi-Finalist, Young Epidemiology Scholars Competition |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. ASH 2024: Clinical Updates in CHIP/CCUS. Invited. Leukemia Research Meeting, US.
- 2024. Myelodysplastic Syndromes: Introduction and Treatment Options. Invited. MDS Patient Conference. Houston, Texas, US.
- 2023. Patterns of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Invited. Leukemia Research Meeting. Houston, TX, US.
- 2022. Risk Stratification of Myelodysplastic Syndromes. Invited. Practical Approach of AML and MDS Treatment. Houston, Texas, US.
- 2022. Malignant Hematology Q&A Session. Invited. MD Anderson Hematology/Medical Oncology Board Review. Houston, TX, US.
- 2022. Clonal Hematopoiesis of Emerging Significance: An Introduction to the MD Anderson CHIP & Leukemia Prevention Clinic. Invited. Leukemia Research Meeting. Houston, TX, US.
- 2022. Clonal Hematopoiesis of Emerging Significance: An Introduction to the MD Anderson CHIP & Leukemia Prevention Clinic. Invited. Division of Cancer Medicine Grand Rounds. Houston, TX, US.
- 2021. Malignant Hematology Q&A Session. Invited. MD Anderson Hematology/Medical Oncology Board Review. Houston, TX, US.
- 2020. Prevention of Therapy-Related Myeloid Neoplasms with CHIP. Invited. T32 Research Symposium. Houston, TX, US.
- 2019. Prevention of Therapy-Related Myeloid Neoplasms with CHIP. Invited. Leukemia Research Meeting. Houston, TX, US.
- 2008. Quantitative Proteomic Analysis of the Met Signaling Network. Conference. Massachusetts Institute of Technology Center for Environmental Health Sciences Annual Poster Session. Cambridge, MA, US.
Regional Presentations
- 2016. Mysterious Abdominal Pain and Inadvertent latrogenesis. Conference. 2016 Society of General Internal Medicine Southern Regional Meeting. Atlanta, GA, US.
- 2012. Thrombotic Thrombocytopenic Purpura in HIV: Not the Usual Suspect. Conference. 2012 Texas Chapter of the American College of Physicians Annual Meeting. Fort Worth, TX, US.
National Presentations
- 2025. YES: Pre-Emptive Treatment of Pre-MDS in the Future. Invited. 2025 MPN-MDS US Focus Meeting. Austin, TX, US.
- 2024. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis. Conference. 2024 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2024. A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients with Myelodysplastic Syndromes After Hypomethylating Agent (HMA) Failure. Conference. 2024 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2024. Risk Stratification in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes: A Multivariate Model. Conference. 2024 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2024. A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients with Myelodysplastic Syndrome After Hypomethylating Agent Failure. Conference. 2024 American Society of Clinical Oncology Annual Meeting. Chicago, IL, US.
- 2023. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes. Conference. 2023 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2023. Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Conference. 2023 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2023. Outcomes of Individuals with Clonal Hematopoiesis Evaluated at a Cancer Center. Conference. 2023 American Society of Clinical Oncology Annual Meeting. Houston, Texas, US.
- 2022. Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure. Conference. 2022 American Society of Hematology Annual Meeting. New Orleans, LA, US.
- 2022. Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies. Conference. 2022 American Society of Hematology Annual Meeting. Houston, Texas, US.
- 2022. Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Conference. 2022 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2020. Final Results from a Phase II Study of Azacitidine and Pembrolizumab in Higher-Risk Myelodysplastic Syndrome after Hypomethylating Agent Failure. Conference. 2020 American Society of Hematology Annual Meeting, US.
- 2020. Updated Results from a Phase II Study of Azacitidine and Pembrolizumab in Higher-Risk Untreated Myelodysplastic Syndrome. Conference. 2020 American Society of Hematology Annual Meeting, US.
- 2019. The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Conference. 2019 American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2019. Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Conference. 2019 American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2019. Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome. Conference. 2019 American Society of Hematology Annual Meeting. Orlando, FL, US.
- 2019. LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents. Conference. 2019 Society of Hematologic Oncology Annual Meeting. Houston, TX, US.
- 2019. Patterns of Leukemic Transformation in Patients with TP53-Mutant Myelodysplastic Syndromes. Conference. 2019 American Society of Clinical Oncology Annual Meeting. Chicago, IL, US.
- 2018. Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Conference. 2018 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2018. Safety and Tolerability of Lurbinectedine (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Conference. 2018 American Society of Hematology Annual Meeting. San Diego, CA, US.
- 2008. Quantitative Proteomic Analysis of the Met Signaling Network. Conference. American Association of Cancer Research Epithelial-Mesenchymal Transition Meeting. Cold Harbor Springs, NY, US.
International Presentations
- 2024. Lower-Risk Myelodysplastic Syndromes: New Therapeutic Strategies. Invited. Dasa Hematology Symposium. Sao Paulo, BR.
- 2024. Genomic Evolution of Patients with Myeloid Neoplasms and Known Antecedent Clonal Hematopoiesis. Conference. 2024 European Hematology Association Annual Congress. Madrid, ES.
- 2024. Risk Stratification in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes: A Multivariate Model. Conference. 2024 European Hematology Association Annual Congress. Madrid, ES.
- 2024. A Phase I Study of the Myeloid Cell Leukemia 1 (MCL1) Inhibitor Tapotoclax (AMG 176) in Patients with Myelodysplastic Syndrome After Hypomethylating Agent Failure. Conference. 2024 European Hematology Association Annual Congress. Madrid, ES.
- 2023. Evolution of IPSS-M Risk Categories in Patients with Myelodysplastic Syndromes from Diagnosis to Hypomethylating Agent Failure. Conference. 2023 European Hematology Association Annual Congress. Frankfurt, DE.
- 2022. Patterns of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Conference. 2022 European Hematology Association Annual Congress. Vienna, AT.
Grant & Contract Support
| Date: | 2025 - 2028 |
| Title: | Improving Clinical Trial Accessibility for Leukemia Prevention and Treatment |
| Funding Source: | Robert A. Winn |
| Role: | PI |
| Date: | 2024 - 2030 |
| Title: | A phase 2 study investigating olutasidenib monotherapy in patients with IDH1-mutated clonal cytopenia of undetermined significance or lower-risk myelodysplastic syndromes/chronic myelomonocytic leukemia |
| Funding Source: | Rigel Pharmaceuticals |
| Role: | PI |
| Date: | 2024 - 2030 |
| Title: | A phase 2 study investigating the combination of olutasidenib and azacitidine in patients with IDH1-mutated higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia or advanced myeloproliferative neoplasms |
| Funding Source: | Rigel Pharmaceuticals |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | Targeting Clonal Hematopoiesis to Prevent AML |
| Funding Source: | Break Through Cancer |
| Role: | Co-PI |
| Date: | 2022 - 2027 |
| Title: | 2021-0276: A Phase 1 Study of AMG 176 as Monotherapy and in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia |
| Funding Source: | Amgen |
| Role: | PI |
| Date: | 2022 - 2025 |
| Title: | An Integrated Approach Towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes |
| Funding Source: | The University of Texas MD Anderson Cancer Center IRG/MRP |
| Role: | Co-I |
| Date: | 2021 - 2024 |
| Title: | 2021-0497: A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications |
| Funding Source: | Karyopharm |
| Role: | Co-PI |
| Date: | 2019 - 2020 |
| Title: | Prevention of Therapy-Related Myeloid Neoplasms with Clonal Hematopoiesis of Indeterminate Potential |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| Date: | 2018 - 2020 |
| Title: | NIH/NCI Research Training in Academic Medical Oncology |
| Funding Source: | NIH/NCI |
| Role: | Trainee |
| ID: | T32 CA009666-24 |
| Date: | 2013 - 2023 |
| Title: | MDS/AML Moon Shot |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
Selected Publications
Peer-Reviewed Articles
- Urrutia S, Chien KS, Li Z, Bazinet A, Tang G, Garcia-Manero G. Cytogenetic annotation automation in myelodysplastic syndrome research databases. Blood Adv 9(10):2428-2430, 2025. e-Pub 2025. PMID: 39983082.
- Tefferi A, Fathima S, Abdelmagid M, Alsugair A, Aperna F, Rezasoltani M, Yousuf M, Natu A, Csizmar CM, Gurney M, Lasho TL, Finke CM, Kanagal-Shamanna R, Hammond D, Chien KS, Bazinet A, DiNardo CD, Kadia TM, Mangaonkar AA, Daver NG, Pardanani AD, Borthakur G, Zepeda-Mendoza CJ, Reichard KK, He R, Loghavi S, Passamonti F, Ravandi F, Sasaki K, Larson D, Garcia-Manero G, Onida F, Gangat N, Montalban-Bravo G, Patnaik MM. BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia. Blood, 2025. e-Pub 2025. PMID: 40332442.
- Chien KS, Braish JS, Li Z, Loghavi S, Bataller A, Montalban-Bravo G, Sasaki K, Kanagal-Shamanna R, Takahashi K, DiNardo CD, Swaminathan M, Kantarjian HM, Garcia-Manero G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39(5):1269-1272, 2025. e-Pub 2025. PMID: 40175627.
- Rodriguez-Sevilla JJ, Ganan-Gomez I, Kumar B, Thongon N, Ma F, Chien KS, Kim YJ, Yang H, Loghavi S, Tan R, Adema V, Li Z, Tanaka T, Uryu H, Kanagal-Shamanna R, Al-Atrash G, Bejar R, Banerjee PP, Lynn Cha S, Montalban-Bravo G, Dougherty M, Fernandez Laurita MC, Wheeler N, Jia B, Papapetrou EP, Izzo F, Duenas DE, McAllen S, Gu Y, Todisco G, Ficara F, Della Porta MG, Jain A, Takahashi K, Clise-Dwyer K, Halene S, Bertilaccio MTS, Garcia-Manero G, Daher M, Colla S. Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nat Commun 16(1):3450, 2025. e-Pub 2025. PMID: 40216768.
- Chien KS, Curry JL, Pemmaraju N, Jain N. Leukemia Cutis in the Setting of Indolent Chronic Lymphocytic Leukemia. Am J Hematol 100(7):1240-1241, 2025. e-Pub 2025. PMID: 40062658.
- Takaoka, K, Komrokji, RS, Chien, KS, Montalban Bravo, G, Salman, JB, Urrutia, S, Bataller Torralba, A, Bazinet, A, Kekedjian, J, Al Ali, NH, Sallman, D, Padron, E, Xie, Z, Kanagal Shamanna, R, Tang, G, Yang, H, Rodriguez-Sevilla, JJ, Garcia-Manero, G, Sasaki, K. Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion. Leukemia Research 150, 2025. e-Pub 2025. PMID: 39938357.
- Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
- Marvin-Peek J, Shelton V, Brassil K, Fellman B, Barr A, Chien KS, Hammond D, Swaminathan M, Jain N, Wierda W, Ferrajoli A, DiNardo C. Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial. Acta Haematol 148(2):233-243, 2025. e-Pub 2025. PMID: 38861934.
- Kantarjian, H, Short, NJ, Haddad, FG, Jain, N, Huang, X, Montalban-Bravo, G, Kanagal-Shamanna, R, Kadia, TM, Daver, N, Chien, KS, Alvarado, Y, Garcia-Manero, G, Issa, GC, Garris, R, Nasnas, C, Nasr, L, Ravandi, F, Jabbour, EJ. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. Journal of Clinical Oncology 42(36):4246-4251, 2024. e-Pub 2024. PMID: 39028925.
- Rodriguez-Sevilla, JJ, Ganan Gomez, I, Ma, F, Chien, KS, Del Rey, M, Loghavi, S, Montalban Bravo, G, Ademà Llobet, V, Wildeman, B, Kanagal Shamanna, R, Bazinet, A, Chifotides, H, Thongon, N, Calvo, X, Hernández, JM, Díez-Campelo, M, Garcia-Manero, G, Colla, S. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38499526.
- Rodriguez-Sevilla JJ, Adema V, Chien KS, Loghavi S, Ma F, Yang H, Montalban-Bravo G, Huang X, Calvo X, Joseph J, Bodden K, Garcia-Manero G, Colla S. The IL-1beta inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial. Nat Commun 15(1):9840, 2024. e-Pub 2024. PMID: 39537648.
- Short, NJ, Nguyen, D, Jabbour, EJ, Senapati, J, Zeng, Z, Issa, GC, Abbas, HA, Nasnas, C, Qiao, W, Huang, X, Borthakur, G, Chien, KS, Haddad, FG, Pemmaraju, N, Karrar, OS, Nguyen, D, Konopleva, M, Kantarjian, HM, Ravandi, F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia. The Lancet Haematology 11(11):e839-e849, 2024. e-Pub 2024. PMID: 39303729.
- Gener-Ricos G, Bataller A, Rodriguez-Sevilla JJ, Chien KS, Quesada AE, Almanza-Huante E, Hammond D, Sasaki K, DiNardo C, Kadia T, Daver N, Borthakur G, Issa GC, Short NJ, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
- Sasaki, K, Kantarjian, HM, Montalban Bravo, G, Hammond, DE, Jabbour, EJ, Kanagal Shamanna, R, Chien, KS, Garcia-Manero, G. Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 24(9):629-633, 2024. e-Pub 2024. PMID: 38777652.
- McCall D, Abuasab T, Rodriguez-Sevilla JJ, Mohamed SF, Patnaik A, Devireddy K, Arani N, Sheikh I, Jamshidi R, Gibson A, Roth M, Nunez C, Garcia M, Chien KS, Loghavi S, Pierce SA, Sasaki K, Issa G, Cuglievan B, Kantarjian H, Garcia-Manero G. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis. Leuk Res 144:107563, 2024. e-Pub 2024. PMID: 39178611.
- Montalban Bravo, G, Jabbour, EJ, Chien, KS, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Konopleva, M, Borthakur, G, Daver, N, Kanagal-Shammana, R, Loghavi, S, Qiao, W, Huang, X, Schneider, H, Meyer, M, Kantarjian, HM, Garcia-Manero, G. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leukemia Research 142, 2024. e-Pub 2024. PMID: 38744144.
- Bataller A, Gener-Ricos G, Almanza-Huante E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
- Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol 42(13):1499-1508, 2024. e-Pub 2024. PMID: 38277619.
- Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
- Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res 30(7):1319-1326, 2024. e-Pub 2024. PMID: 38300723.
- Montalban Bravo, G, Jabbour, EJ, Borthakur, G, Kadia, TM, Ravandi-Kashani, F, Chien, KS, Pemmaraju, N, Hammond, DE, Dong, XQ, Huang, X, Schneider, H, John, RB, Kanagal-Shamana, R, Loghavi, S, Kantarjian, HM, Garcia-Manero, G. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. British Journal of Haematology 204(3):898-909, 2024. e-Pub 2024. PMID: 37946611.
- Bataller, A, Montalban Bravo, G, Bazinet, A, Alvarado, Y, Chien, KS, Venugopal, S, Ishizawa, J, Hammond, DE, Swaminathan, M, Sasaki, K, Issa, GC, Short, NJ, Masarova, L, Daver, N, Kadia, TM, Colla, S, Qiao, W, Huang, X, Kanagal Shamanna, R, Hendrickson, S, Ravandi-Kashani, F, Jabbour, EJ, Kantarjian, HM, Garcia-Manero, G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. The Lancet Haematology 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Med 13(5):e7093, 2024. e-Pub 2024. PMID: 38497538.
- Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
- Montalban Bravo, G, Kanagal Shamanna, R, Li, Z, Hammond, DE, Chien, KS, Rodriguez-Sevilla, JJ, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. British Journal of Haematology 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
- Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol 98(11):1780-1790, 2023. e-Pub 2023. PMID: 37665752.
- Chien KS, Peterson CB, Young E, Chihara D, Manasanch EE, Ramdial JL, Thompson PA. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. Blood Adv 7(19):5691-5697, 2023. e-Pub 2023. PMID: 36696472.
- DiNardo, C, Venugopal, S, Lachowiez, C, Takahashi, K, Loghavi, S, Montalban Bravo, G, Wang, X, Carraway, H, Sekeres, MA, Sukkur, A, Hammond, DE, Chien, KS, Maiti, A, Masarova, L, Sasaki, K, Alvarado, Y, Kadia, TM, Short, NJ, Daver, N, Borthakur, G, Ravandi-Kashani, F, Kantarjian, HM, Patel, BJ, Dezern, A, Roboz, G, Garcia-Manero, G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Advances 7(11):2378-2387, 2023. e-Pub 2023. PMID: 35973199.
- Urrutia, S, Li, Z, Almanza, E, Bataller, A, Kanagal Shamanna, R, Senapati, J, Sasaki, K, Chien, KS, Montalban Bravo, G, DiNardo, C, Borthakur, G, Bueso-Ramos, CE, Pierce, S, Kantarjian, HM, Garcia-Manero, G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37(6):1397-1400, 2023. e-Pub 2023. PMID: 37185307.
- Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2023. PMID: 36458426.
- Jabbour, EJ, Short, NJ, Jain, N, Huang, X, Montalban Bravo, G, Banerjee, PP, Rezvani, K, Jiang, XL, Kim, KH, Kanagal Shamanna, R, Khoury, J, Patel, KP, Kadia, TM, Daver, N, Chien, KS, Alvarado, Y, Garcia-Manero, G, Issa, GC, Haddad, FG, Kwari, M, Thankachan, J, Delumpa, R, Macaron, W, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Haematology 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
- Zuo, Z, Medeiros, LJ, Garces, S, Routbort, MJ, Ok, CY, Loghavi, S, Kanagal Shamanna, R, Jelloul, FZ, Garcia-Manero, G, Chien, KS, Patel, KP, Luthra, R, Yin, CC. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology 12(1), 2023. e-Pub 2023. PMID: 36671709.
- Venugopal, S, DiNardo, C, Loghavi, S, Qiao, W, Ravandi-Kashani, F, Konopleva, M, Kadia, TM, Bhalla, K, Jabbour, EJ, Issa, GC, Macaron, W, Daver, N, Borthakur, G, Montalban Bravo, G, Yilmaz, M, Patel, KP, Kanagal Shamanna, R, Chien, KS, Maiti, A, Kantarjian, HM, Short, NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. American journal of hematology 97(12):1560-1567, 2022. e-Pub 2022. PMID: 36087091.
- Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganan-Gomez I, Montalban-Bravo G, Chien KS, Do KA, Daver N, Garcia-Manero G. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 63(13):3154-3164, 2022. e-Pub 2022. PMID: 36059252.
- Darbaniyan, F, Zheng, H, Kanagal Shamanna, R, Lockyer, P, Montalban Bravo, G, Estecio, MR, Lu, Y, Soltysiak, KA, Chien, KS, Yang, H, Sasaki, K, Class, CA, Ganan Gomez, I, Do, K, Garcia-Manero, G, Wei, Y. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Experimental Hematology 115:44-53, 2022. e-Pub 2022. PMID: 36150563.
- Kim, K, Ong, F, Montalban Bravo, G, Kanagal Shamanna, R, Kadia, TM, Jabbour, EJ, Alvarado, Y, Sasaki, K, Dong, XQ, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Chien, KS, Garcia-Manero, G. MDS-406 Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 22:S310, 2022. e-Pub 2022. PMID: 36163955.
- Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
- Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. e-Pub 2022. PMID: 36163957.
- Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
- Ong, F, Kim, K, Kanagal Shamanna, R, DiNardo, C, Takahashi, K, Kadia, TM, Jabbour, EJ, Short, NJ, Hammond, DE, Pemmaraju, N, Pierce, S, Montalban Bravo, G, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH). Clinical Lymphoma, Myeloma and Leukemia 22:S319, 2022. e-Pub 2022. PMID: 36163972.
- Bazinet, A, Darbaniyan, F, Jabbour, EJ, Montalban Bravo, G, Ohanian, M, Chien, KS, Kadia, TM, Takahashi, K, Masarova, L, Short, NJ, Alvarado, Y, Yilmaz, M, Ravandi-Kashani, F, Andreeff, M, Kanagal Shamanna, R, Ganan Gomez, I, Colla, S, Qiao, W, Huang, X, McCue, D, Mirabella, B, Kantarjian, HM, Garcia-Manero, G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. The Lancet Haematology 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
- Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, N, Kadia, TM, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia 22:S321, 2022. e-Pub 2022. PMID: 36163977.
- Yang, H, Garcia-Manero, G, Sasaki, K, Montalban Bravo, G, Tang, Z, Wei, Y, Kadia, TM, Chien, KS, Rush, D, Nguyen, H, Kalia, A, Nimmakayalu, M, Bueso-Ramos, CE, Kantarjian, HM, Medeiros, LJ, Luthra, R, Kanagal Shamanna, R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia 36(9):2306-2316, 2022. e-Pub 2022. PMID: 35915143.
- Desikan, SP, Ravandi-Kashani, F, Pemmaraju, N, Konopleva, M, Loghavi, S, Jabbour, EJ, Daver, N, Jain, N, Chien, KS, Maiti, A, Montalban Bravo, G, Kadia, TM, Macaron, W, Delumpa, R, Kwari, M, Borthakur, G, Short, NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta haematologica 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
- Ganan Gomez, I, Yang, H, Ma, F, Montalban Bravo, G, Thongon, N, Marchica, V, Richard-Carpentier, G, Chien, KS, Manyam, GC, Wang, F, Alfonso Pierola, A, Chen, S, Class, CA, Kanagal Shamanna, R, Ingram, JP, Ogoti, Y, Rose, A, Loghavi, S, Lockyer, P, Cambo, B, Muftuoglu, M, Schneider, S, Ademà Llobet, V, McLellan, MD, Garza, J, Marchesini, M, Giuliani, N, Pellegrini, M, Wang, J, Walker, J, Li, Z, Takahashi, K, Leverson, JD, Bueso-Ramos, CE, Andreeff, M, Dwyer, KC, Garcia-Manero, G, Colla, S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature medicine 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
- Saxena, K, Jabbour, EJ, Issa, GC, Sasaki, K, Ravandi-Kashani, F, Maiti, A, Daver, N, Kadia, TM, DiNardo, C, Konopleva, M, Cortes, JE, Yilmaz, M, Chien, KS, Pierce, S, Kantarjian, HM, Short, NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. Journal of Hematology and Oncology 14(1), 2021. e-Pub 2021. PMID: 34130720.
- Chien, KS, Kim, K, Nogueras Gonzalez, G, Borthakur, G, Naqvi, K, Daver, N, Montalban Bravo, G, Cortes, JE, DiNardo, C, Jabbour, EJ, Alvarado, Y, Andreeff, M, Bose, P, Jain, N, Kadia, TM, Huang, X, Sheppard, KB, Klingner-Winton, C, Pierce, S, Dong, XQ, Soltysiak, KA, Kantarjian, HM, Garcia-Manero, G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. British Journal of Haematology 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
- Kanagal Shamanna, R, Montalban Bravo, G, Sasaki, K, Darbaniyan, F, Jabbour, EJ, Bueso-Ramos, CE, Wei, Y, Chien, KS, Kadia, TM, Ravandi-Kashani, F, Borthakur, G, Soltysiak, KA, Routbort, MJ, Patel, KP, Pierce, S, Medeiros, LJ, Kantarjian, HM, Garcia-Manero, G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127(19):3552-3565, 2021. e-Pub 2021. PMID: 34161603.
- Lachowiez, C, Loghavi, S, Furudate, K, Montalban Bravo, G, Maiti, A, Kadia, TM, Daver, N, Borthakur, G, Pemmaraju, N, Sasaki, K, Alvarado, Y, Yilmaz, M, Short, NJ, Chien, KS, Ohanian, M, Pierce, S, Patel, KP, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, Garcia-Manero, G, Takahashi, K, Konopleva, M, DiNardo, C. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Advances 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
- Montalban Bravo, G, Darbaniyan, F, Kanagal Shamanna, R, Ganan Gomez, I, Class, CA, Sasaki, K, Naqvi, K, Wei, Y, Yang, H, Soltysiak, KA, Chien, KS, Bueso-Ramos, CE, Do, K, Kantarjian, HM, Garcia-Manero, G. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leukemia Research 101, 2021. e-Pub 2021. PMID: 33517186.
- Garcia-Manero, G, Chien, KS, Montalban Bravo, G. Myelodysplastic syndromes. American journal of hematology 95(11):1399-1420, 2020. e-Pub 2020. PMID: 32744763.
- Chien, KS, Class, CA, Montalban Bravo, G, Wei, Y, Sasaki, K, Naqvi, K, Ganan Gomez, I, Yang, H, Soltysiak, KA, Kanagal Shamanna, R, Do, K, Kantarjian, HM, Garcia-Manero, G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leukemia and Lymphoma 61(6):1493-1499, 2020. e-Pub 2020. PMID: 32036728.
- Montalban Bravo, G, Class, CA, Ganan Gomez, I, Kanagal Shamanna, R, Sasaki, K, Richard-Carpentier, G, Naqvi, K, Wei, Y, Yang, H, Soltysiak, KA, Chien, KS, Bueso-Ramos, CE, Do, K, Kantarjian, HM, Garcia-Manero, G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia 34(3):872-881, 2020. e-Pub 2020. PMID: 31719677.
- Montalban Bravo, G, Kanagal Shamanna, R, Benton, CB, Class, CA, Chien, KS, Sasaki, K, Naqvi, K, Alvarado, Y, Kadia, TM, Ravandi-Kashani, F, Daver, N, Takahashi, K, Jabbour, EJ, Borthakur, G, Pemmaraju, N, Konopleva, M, Soltysiak, KA, Pierce, S, Bueso-Ramos, CE, Patel, KP, Kantarjian, HM, Garcia-Manero, G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances 4(3):482-495, 2020. e-Pub 2020. PMID: 32027746.
- Benton, CB, Chien, KS, Tefferi, A, Rodriguez, J, Ravandi-Kashani, F, Daver, N, Jabbour, EJ, Jain, N, Alvarado, Y, Kwari, M, Pierce, S, Maiti, A, Hornbaker, MJ, Albuquerque Almeida Santos, M, Martinez, S, Siguero, M, Zblewski, D, Al-Kali, A, Hogan, WJ, Kantarjian, HM, Pardanani, A, Garcia-Manero, G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematological Oncology 37(1):96-102, 2019. e-Pub 2019. PMID: 30153704.
- Pandey, A, Sarangi, S, Chien, KS, Sengupta, P, Papa, AL, Basu, S, Sengupta, S. Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery. Nanotechnology 25(44), 2014. e-Pub 2014. PMID: 25302488.
Review Articles
- Chien KS, DiNardo CD, Garcia-Manero G. Clonal hematopoiesis: malignant implications, extrahematologic manifestations, and management. Clin Adv Hematol Oncol 22(7):320-327, 2024. e-Pub 2024. PMID: 39110659.
- Chiu, CY, Matsuo, T, Wurster, ST, Gerstein, YS, Hammond, DE, Chien, KS, DiNardo, C, Kontoyiannis, DP. Invasive mucorales sinusitis in a young patient with Emberger syndrome and newly diagnosed AML. Mycoses 66(12):1029-1034, 2023. e-Pub 2023. PMID: 37550272.
- Carvour, ML, Ayyar, BK, Chien, KS, Ramirez, NC, Yamamoto, H. A patient-centered approach to postgraduate trainee health and wellness. Academic Medicine 91(9):1205-1210, 2016. e-Pub 2016. PMID: 27415444.
Other Articles
- Farmakiotis, D, Chien, KS, Shum, TT, Rodriguez-Barradas, MC, Musher, DM Photo quiz. Clinical Infectious Diseases 56(7):1003+1052-1053, 2013. PMID: 23463794.
Abstracts
- Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Outcomes of Individuals with Clonal Hematopoiesis Evaluated at a Cancer Center. 2023 European Hematology Association Annual Congress, 2023. e-Pub 2023.
- Chien KS, Class CA, Montalban-Bravo G, Sasaki K, Naqvi K, Ganan-Gomez I, Wei Y, Yang H, Kanagal-Shamanna R, Soltysiak KA, Kantarjian HM, Garcia-Manero G. LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents. 2019 American Society of Clinical Oncology Annual Meeting, 2019. e-Pub 2019.
Book Chapters
- Chien KS, Bueso-Ramos C, Garcia-Manero G. Chapter 5: Myelodysplastic Syndromes: The MD Anderson Cancer Center Approach. In: The MD Anderson Manual of Medical Oncology, Fourth Edition, 2022.
Letters to the Editor
- Tremblay, D, Csizmar, C, DiNardo, C, Ball, S, Rippel, N, Hammond, DE, Kadia, TM, Ravandi, F, Chien, KS, Van Hyfte, G, Mazumdar, M, Saliba, AN, Mangaonkar, AA, Lasho, T, Al-Kali, A, Kremyanskaya, M, Feld, J, Silverman, LR, Komrokji, RS, Mascarenhas, J, Padron, E, Garcia-Manero, G, Sallman, D, Patnaik, MM, Montalban Bravo, G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia. Leukemia 39: 257-260, 2025.
- Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, Kadia, TM, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14, 2024.
- Kontoyiannis, PD, Peddireddy, A, Sasaki, K, Chien, KS, Senapati, J, Montalban Bravo, G, DiNardo, C, Borthakur, G, Kanagal-Shamanna, R, Bueso-Ramos, CE, Pierce, S, Kantarjian, HM, Garcia-Manero, G, Urrutia, S. Causes of death in patients with myelodysplastic syndrome and spliceosome mutations. Leukemia Research 147, 2024.
- Chien KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, Hammond DE, Swaminathan M, Bazinet A, Kimberley J, Bodden K, Schneider H, Dong XQ, Pierce SA, Huang X, Jabbour EJ, Kantarjian HM, Garcia-Manero G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leuk Res 147: 107602, 2024.
- Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
- Csizmar, C, Gurney, M, Kanagal-Shamanna, R, Chien, KS, Hammond, DE, Lasho, T, Finke, C, Dean, C, Natu, A, Mangaonkar, AA, Al-Kali, A, Gangat, N, Tefferi, A, Alkhateeb, HB, Garcia-Manero, G, Komrokji, RS, Ali, NA, Padron, E, Montalban Bravo, G, Patnaik, MM. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica 109: 3419-3425, 2024.
- Montalban Bravo, G, Rodriguez-Sevilla, JJ, Swanson, DM, Kanagal Shamanna, R, Hammond, DE, Chien, KS, Sasaki, K, Jabbour, EJ, DiNardo, C, Takahashi, K, Short, NJ, Issa, GC, Pemmaraju, N, Kadia, TM, Ravandi-Kashani, F, Daver, N, Borthakur, G, Loghavi, S, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Garcia-Manero, G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.
- Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98: E281-E284, 2023.
- Bataller, A, Chien, KS, Sasaki, K, Montalban Bravo, G, Kanagal Shamanna, R, Urrutia, S, Almanza-Huante, E, Gener-Ricos, G, Ravandi-Kashani, F, Jabbour, EJ, Kadia, TM, Borthakur, G, Garcia-Manero, G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leukemia Research 127, 2023.
- Siddiqui, MT, Konoplev, SN, Issa, GC, Kantarjian, HM, Daver, N, Ravandi-Kashani, F, Kadia, TM, Tang, G, Wang, SA, Thakral, B, Medeiros, LJ, Pozdnyakova, O, Pierce, S, Montalban Bravo, G, Chien, KS, Hammond, DE, Sasaki, K, Garcia-Manero, G, Hasserjian, RP. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements. American journal of hematology 98: E91-E94, 2023.
- Montalban Bravo, G, Kanagal Shamanna, R, Darbaniyan, F, Siddiqui, MT, Sasaki, K, Wei, Y, Yang, H, Chien, KS, Naqvi, K, Jabbour, EJ, Kadia, TM, Daver, N, DiNardo, C, Ravandi-Kashani, F, Pemmaraju, N, Bose, P, Verstovsek, S, Pierce, S, Bueso-Ramos, CE, Patel, KP, Do, K, Kantarjian, HM, Garcia-Manero, G. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). American journal of hematology 96: E246-E249, 2021.
- Kanagal Shamanna, R, Montalban Bravo, G, Katsonis, P, Sasaki, K, Class, CA, Jabbour, EJ, Sallman, D, Hunter, AM, Benton, CB, Chien, KS, Luthra, R, Bueso-Ramos, CE, Kadia, TM, Andreeff, M, Komrokji, RS, Al Ali, NH, Short, NJ, Daver, N, Routbort, MJ, Khoury, J, Patel, KP, Ganan Gomez, I, Wei, Y, Borthakur, G, Ravandi-Kashani, F, Do, K, Soltysiak, KA, Lichtarge, O, Medeiros, LJ, Kantarjian, HM, Garcia-Manero, G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood cancer journal 11, 2021.
- Sasaki, K, Montalban Bravo, G, Kanagal Shamanna, R, Jabbour, EJ, Ravandi-Kashani, F, Kadia, TM, Daver, N, Pemmaraju, N, Konopleva, M, Borthakur, G, Takahashi, K, Patel, KP, Soltysiak, KA, Chien, KS, Sakurai, K, Pierce, S, Kantarjian, HM, Garcia-Manero, G. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American journal of hematology 95: E326-E329, 2020.
- Chien, KS, Farmakiotis, D, Rodriguez-Barradas, MC, Musher, DM. It's not that simple. Clinical Infectious Diseases 56: 308, 2013.
Patient Reviews
CV information above last modified July 21, 2025